Mapping lymph nodes in cancer management - Role of 99mTc-tilmanocept injection

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1151-1158

  Tausch, Christoph ^a   Baege, Astrid ^a   Rageth, Christoph ^a  

^a Brust Zentrum   (Switzerland)

Author keywords

Lymphatic mapping; New tracer; Sentinel lymph node

Indexed keywords

ALBUMIN TC 99M COLLOID; DYE; INDOCYANINE GREEN; MANNOSE RECEPTOR; TECHNETIUM SULFUR COLLOID TC 99M; TILMANOCEPT TC 99M; UNCLASSIFIED DRUG; VITAL BLUE DYE;

ARTICLE; BREAST CANCER; CANCER MODEL; CELLULAR DISTRIBUTION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG UPTAKE; FALSE NEGATIVE RESULT; FLUORESCENCE IMAGING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM EXAMINATION; MELANOMA; MOLECULAR SIZE; MOUTH SQUAMOUS CELL CARCINOMA; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETICULOENDOTHELIAL SYSTEM; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE MAPPING; SENTINEL LYMPH NODE METASTASIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TISSUE DISTRIBUTION; UTERINE CERVIX CANCER; VITAL STAIN;

EID: 84903137904     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S50394     Document Type: Article

References (79)

1. ChenSL, Iddings DM, Scheri RP, Bilchik AJ. Lymphatic mapping andsentinelnode analysis: current concepts and applications. CA Cancer J Clin. 2006;56(5):292-309.
2. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39(2):456-466.
3. Morton DL, Wen DR, Wong JH, etal. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4): 392-399.
4. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335-339.
5. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3): 391-398.
6. Albertini JJ, Lyman GH, Cox C, etal. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276: 1818-1822.
7. Pijpers R, Meijer S, Hoekstra OS, etal. Impact of lymphoscintigraphy on sentinel node identification with technetium-99mcolloidal albumin in breast cancer. J Nucl Med. 1997;38:366-368.
8. Veronesi U, Paganelli G, Galimberti V, etal. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 1997;349:1864-1867.
9. Krag D, Weaver D, Ashikaga T, etal. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med. 1998;339(14): 941-946.
10. McMasters KM, Tuttle TM, Carlson DJ, etal. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18(13):2560-2566.
11. Noguchi M, Motomura K, Imoto S, etal. A multicenter validation study of sentinel lymph node biopsy by the Japanese Breast Cancer Society. Breast Cancer Res Treat. 2000;63(1):31-40.
12. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226(3):271-276.
13. Greene FL, Page DL, Fleming ID, etal. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
14. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19(18):3817-3827.
15. Lyman GH, Giuliano AE, Somerfield MR, etal. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30): 7703-7720.
16. Krag DN, Anderson SJ, Julian TB, etal. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-933.
17. Ashikaga T, Krag DN, Land SR, etal. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111-118.
18. Mansel RE, Fallowfield L, Kissin M, etal. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9): 599-609.
19. Moody LC, Wen X, McKnight T, Chao C. Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer. Surgery. 2012;152(3):389-396.
20. Schrenk P, Hochreiner G, Fridrik M, Wayand W. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J. 2003;9(4):282-287.
21. Schrenk P, Tausch C, Wölfl S, Bogner S, Fridrik M, Wayand W. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes. Am J Surg. 2008;196(2):176-183.
22. Kuehn T, Bauerfeind I, Fehm T, etal. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-618.
23. Mamounas EP, Brown A, Anderson S, etal. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694-2702.
24. Tausch C, Steger GG, Haid A, etal. Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14. Breast J. 2011;17(3):230-238.
25. Boughey JC, Suman VJ, Mittendorf EA, etal. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-1461.
26. Chen JJ, Wu J. Management strategy of early-stage breast cancer patients with a positive sentinel lymph node: with or without axillary lymph node dissection. Crit Rev Oncol Hematol. 2011;79(3):293-301.
27. Bilimoria KY, Bentrem DJ, Hansen NM, etal. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18): 2946-2953.
28. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, etal. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17 Suppl 3:343-351.
29. Milgrom S, Cody H, Tan L, etal. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 2012;19(12):3762-3770.
30. Giuliano AE, McCall L, Beitsch P, etal. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-432.
31. Giuliano AE, Hunt KK, Ballman KV, etal. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6): 569-575.
32. Galimberti V, Cole BF, Zurrida S, etal. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305.
33. Wong SL, Balch CM, Hurley P, etal. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol. 2012;19:3313-3324.
34. Morton DL, Thompson JF, Cochran AJ, etal. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599-609.
35. Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med. 2014;370(7):663-664.
36. Matthey-Giè M, Boubaker A, Letovanec I, Demartines N, Matter M. Sentinel lymph node biopsy in nonmelanoma skin cancer patients. J Skin Cancer. 2013;2013:267474.
37. van der Zaag ES, Kooij N, van de Vijver MJ, Bemelman WA, Peters HM, Buskens CJ. Diagnosing occult tumour cells and their predictive value in sentinel nodes of histologically negative patients with colorectal cancer. Eur J Surg Oncol. 2010;36:350-357.
38. Saha S, Johnston G, Korant A, etal. Aberrant drainage of sentinel lymph nodes in colon cancer and its impact on staging and extent of operation. Am J Surg. 2013;205:302-305.
39. van der Zaag ES, Bouma WH, Tanis PJ, Ubbink DT, Bemelman WA, Buskens CJ. Systematic review of sentinel lymph node mapping procedure in colorectal cancer. Ann Surg Oncol. 2012;19:3449-3459.
40. Bembenek AE, Rosenberg R, Wagler E, etal. Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg. 2007;245:858-863.
41. Retter SM, Herrmann G, Schiedeck TH. Clinical value of sentinel node mapping in carcinoma of the colon. Colorectal Dis. 2011;13: 855-859.
42. Resch A, Langner C. Lymph node staging in colorectal cancer: old controversies and recent advances. World J Gastroenterol. 2013;19(46): 8515-8526.
43. Mistrangelo DM, Bellò M, Cassoni P, etal. Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature. Br J Cancer. 2013;108(3):527-532.
44. Filip B, Scarpa M, Cavallin F, Alfieri R, Cagol M, Castoro C. Minimally invasive surgery for esophageal cancer: a review on sentinel node concept. Surg Endosc. 2014;28(4):1238-1249.
45. Takeuchi H, Kawakubo H, Takeda F, Omori T, Kitagawa Y. Sentinel node navigation surgery in early-stage esophageal cancer. Ann Thorac Cardiovasc Surg. 2012;18(4):306-313.
46. Can MF, Yagci G, Cetiner S. Systematic review of studies investigating sentinel node navigation surgery and lymphatic mapping for gastric cancer. J Laparoendosc Adv Surg Tech A. 2013;23(8):651-662.
47. Miyashiro I, Hiratsuka M, Sasako M, et al. Gastric Cancer Surgical Study Group (GCSSG) in the Japan Clinical Oncology Group (JCOG). High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302. Gastric Cancer. 2014;17(2):316-323.
48. Palla VV, Karaolanis G, Moris D, Antsaklis A. Sentinel lymph node biopsy in uterine cervical cancer patients: ready for clinical use? A review of the literature. ISRN Surg. 2014;2014:841618.
49. Hassanzade M, Attaran M, Treglia G, Yousefi Z, Sadeghi R. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;130(1):237-245.
50. Levenback CF, Ali S, Coleman RL, etal. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012;30(31):3786-3791.
51. Sadeghi R, Gholami H, Zakavi SR, Kakhki VR, Tabasi KT, Horenblas S. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature. J Urol. 2012;187(1):25-31.
52. Yamauchi K, Kogashiwa Y, Nakamura T, Moro Y, Nagafuji H, Kohno N. Diagnostic evaluation of sentinel lymph node biopsy in early head and neck squamous cell carcinoma: A meta-analysis. Head Neck. Epub 2013 Oct 25.
53. Gilmore DM, Khullar OV, Colson YL. Developing intrathoracic sentinel lymph node mapping with near-infrared fluorescent imaging in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144(3):S80-S84.
54. Winter A, Kneib T, Henke RP, Wawroschek F. Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics. Int J Urol. 2014;21(1):58-63.
55. Goyal A, Newcombe RG, Chhabra A, Mansel RE; ALMANAC Trialists Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99(2):203-208.
56. Veronesi U, Paganelli G, Viale G, etal. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91(4):368-373.
57. Martin RC 2nd, Edwards MJ, Wong SL, etal. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000;128(2):139-144.
58. Krag DN, Anderson SJ, Julian TB, etal. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881-888.
59. Chagpar AB, Martin RC, Scoggins CR, etal. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery. 2005;138(1): 56-63.
60. Rodier JF, Velten M, Wilt M, etal. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol. 2007;25(24): 3664-3669.
61. Motomura K, Inaji H, Komoike Y, Kasugai T, Noguchi S, Koyama H. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol. 1999;29(12):604-607.
62. Jung SY, Kim SK, Kim SW, etal. Comparison of sentinel lymph node biopsy guided by the multimodal method of indocyanine green fluorescence, radioisotope, and blue dye versus the radioisotope method in breast cancer: a randomized controlled trial. Ann Surg Oncol. 2014;21(4):1254-1259.
63. Verbeek FP, Troyan SL, Mieog JS, etal. Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Res Treat. 2014;143(2):333-342.
64. Ballardini B, Santoro L, Sangalli C, etal. The ndocyanine green method is equivalent to the 99mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: a concordance and validation study. Eur J Surg Oncol. 2013;39(12):1332-1336.
65. Sugie T, Sawada T, Tagaya N, etal. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol. 2013;20(7):2213-2218.
66. Douek M, Klaase J, Monypenny I, etal. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG multicentre trial. Ann Surg Oncol. 2014;21(4):1237-1245.
67. Wallace AM, Hoh CK, Vera DR, Darrah D, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531-538.
68. Leong SP, Kim J, Ross MI, etal. A phase 2 study of (99m) Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Ann Surg Oncol. 2011;18:961-969.
69. Wallace AM, Hoh CK, Ellner SJ, Darrah DD, Schulteis G, Vera DR. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007;14:913-921.
70. Wallace AM, Hoh CK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol. 2007;34:849-853.
71. Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: (99m) Tc-DTPA-mannosyl-dextran. J Nucl Med. 2001;42:951-959.
72. Méndez J, Wallace AM, Hoh CK, Vera DR. Detection of gastric and colonic sentinel nodes through endoscopic administration of 99mTc-DTPA-mannosyl-dextran in pigs. J Nucl Med. 2003;44(10):1677-1681.
73. Ellner SJ, Hoh CK, Vera DR, Darrah DD, Schulteis G, Wallace AM. Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol. 2003;30(8):805-810.
74. Wallace AM, Han LK, Povoski SP, etal. Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol. 2013;20(8): 2590-2599.
75. Sondak VK, King DW, Zager JS, etal. Combined analysis of phase III trials evaluating [99mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20(2):680-688.
76. Tokin CA, Cope FO, Metz WL, etal. The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care. Clin Exp Metastasis. 2012;29(7):681-686.
77. Marcinow AM, Hall N, Byrum E, Teknos TN, Old MO, Agrawal A. Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study. JAMA Otolaryngol Head Neck Surg. 2013;139(9):895-902.
78. Veronesi U, Paganelli G, Viale G, etal. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-553.
79. Goldhirsch A, Wood WC, Coates AS, etal. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736-1747.